The efficacy and safety of a 577-nm high-power optically pumped semiconductor laser in the treatment of postacne erythema.
577-nm high-power optically pumped semiconductor laser (HOPSL)
Postacne erythema
Vascular-specific laser
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
03
04
2020
revised:
27
04
2020
accepted:
30
04
2020
pubmed:
10
5
2020
medline:
15
5
2021
entrez:
9
5
2020
Statut:
ppublish
Résumé
Postacne erythema (PAE) is a common sequela of inflammatory acne vulgaris, treatment of which has been challenging due to limited options available and the variability of results for each modality. Recently, a 577-nm high-power optically pumped semiconductor laser (HOPSL) initially developed for vascular lesions has shown promising results for the treatment of PAE. To evaluate the efficacy and safety of 577-nm HOPSL in the treatment of postacne erythema. This was a split-face, randomized controlled trial pilot study. Twenty-one patients with PAE on both sides of their face were enrolled. Each subject's face sides were randomly assigned to either receive 577-nm HOPSL treatment (QuadroStar PRO™, Asclepion Laser Technologies) using the scanner handpiece, 1mm spot size, 80% coverage, 12-15 J/cm Upon completion of the treatment period, the mean EI was significantly decreased in both treated and nontreated sides of the face (P < .001 and P = .001, respectively). The laser-treated sides already demonstrated significant reduction in the mean EI compared with nontreated sides at 1 month after the 2nd treatment (P = .007). The mean MI of both sides, however, did not show any statistically significant differences from baseline, and likewise when comparing between sides. Patients reported more improvement on laser-treated sides compared with nontreated sides. Reported side effects were limited to mild discomfort during treatment and transient facial erythema lasting approximately 30 minutes. Patients who received treatment with the 577-nm HOPSL had better outcomes with minimal side effects at 1 month after 2 treatments as compared to those who did not receive any treatment. Therefore, the 577-nm HOPSL may be considered as an effective adjuvant treatment for PAE and early erythematous atrophic scars.
Sections du résumé
BACKGROUND
BACKGROUND
Postacne erythema (PAE) is a common sequela of inflammatory acne vulgaris, treatment of which has been challenging due to limited options available and the variability of results for each modality. Recently, a 577-nm high-power optically pumped semiconductor laser (HOPSL) initially developed for vascular lesions has shown promising results for the treatment of PAE.
AIMS
OBJECTIVE
To evaluate the efficacy and safety of 577-nm HOPSL in the treatment of postacne erythema.
METHODS
METHODS
This was a split-face, randomized controlled trial pilot study. Twenty-one patients with PAE on both sides of their face were enrolled. Each subject's face sides were randomly assigned to either receive 577-nm HOPSL treatment (QuadroStar PRO™, Asclepion Laser Technologies) using the scanner handpiece, 1mm spot size, 80% coverage, 12-15 J/cm
RESULTS
RESULTS
Upon completion of the treatment period, the mean EI was significantly decreased in both treated and nontreated sides of the face (P < .001 and P = .001, respectively). The laser-treated sides already demonstrated significant reduction in the mean EI compared with nontreated sides at 1 month after the 2nd treatment (P = .007). The mean MI of both sides, however, did not show any statistically significant differences from baseline, and likewise when comparing between sides. Patients reported more improvement on laser-treated sides compared with nontreated sides. Reported side effects were limited to mild discomfort during treatment and transient facial erythema lasting approximately 30 minutes.
CONCLUSION
CONCLUSIONS
Patients who received treatment with the 577-nm HOPSL had better outcomes with minimal side effects at 1 month after 2 treatments as compared to those who did not receive any treatment. Therefore, the 577-nm HOPSL may be considered as an effective adjuvant treatment for PAE and early erythematous atrophic scars.
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1642-1647Subventions
Organisme : Faculty of Medicine Siriraj Hospital, Mahidol University
Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Karimkhani C, Dellavalle RP, Coffeng LE, et al. Global skin disease morbidity and mortality: an update from the global burden of disease study 2013. JAMA Dermatol. 2017;153(5):406-412.
Bae-Harboe Y-S, Graber EM. Easy as PIE (postinflammatory erythema). J Clin Aesthet Dermatol. 2013;6(9):46.
Chandrashekar BS, Ashwini KR, Vasanth V, Navale S. Retinoic acid and glycolic acid combination in the treatment of acne scars. Indian Dermatol Online J. 2015;6(2):84.
Genedy RM. Topical brimonidine tartrate as a novel treatment for facial erythema of rosacea and acne erythema. J Egypt Womens Dermatol Soc. 2016;13(2):55-64.
Min S, Park SY, Yoon JY, Kwon HH, Suh DH. Fractional Microneedling Radiofrequency Treatment for Acne-related Post-inflammatory Erythema. Acta Derm Venereol. 2016;96(1):87-91.
Jakhar D, Kaur I. Topical 5% Tranexamic acid for acne-related post inflammatory erythema. J Am Acad Dermatol. 2020;82(6):e187-e188.
Kurokawa I, Yoshioka M, Ito S. Split-face comparative clinical trial using glyceryl-octyl-ascorbic acid/ascorbyl 2-phosphate 6-palmitate/DL-α-tocopherol phosphate complex treatment for postinflammatory hyperpigmentation, postinflammatory erythema and atrophic scar in acne vulgaris. J Dermatol. 2019;46(10):e347.
Yeung CK, Shek SY, Bjerring P, Yu CS, Kono T, Chan HH. A Comparative study of intense pulsed light alone and its combination with photodynamic therapy for the treatment of facial acne in Asian skin. Lasers Surg Med. 2007;39(1):1-6.
Kapicioglu Y, Sarac G, Cenk H. Treatment of erythematotelangiectatic rosacea, facial erythema, and facial telangiectasia with a 577-nm pro-yellow laser: a case series. Lasers Med Sci. 2019;34(1):93-98.
Alster TS, McMeekin TO. Improvement of facial acne scars by the 585 nm flashlamp-pumped pulsed dye laser. J Am Acad Dermatol. 1996;35(1):79-87.
Min S, Park S, Yoon J, Kwon H, Suh D. Fractional microneedling radiofrequency treatment for acne-related post-inflammatory erythema. Acta Dermatovenereol. 2016;96(1):87-91.
Panchaprateep R, Munavalli G. Low-fluence 585 nm Q-switched Nd: YAG laser: a novel laser treatment for post-acne erythema. Lasers Surg Med. 2015;47(2):148-155.
Park KY, Ko EJ, Seo SJ, Hong CK. Comparison of fractional, nonablative, 1550-nm laser and 595-nm pulsed dye laser for the treatment of facial erythema resulting from acne: a split-face, evaluator-blinded, randomized pilot study. J Cosmet Laser Ther. 2014;16(3):120-123.
Wat H, Wu DC, Rao J, Goldman MP. Application of intense pulsed light in the treatment of dermatologic disease: a systematic review. Dermatol Surg. 2014;40(4):359-377.
Mathew ML, Karthik R, Mallikarjun M, Bhute S, Varghese A. Intense pulsed light therapy for acne-induced post-inflammatory erythema. Indian Dermatol Online J. 2018;9(3):159.
Guigou S, Cassian M, Parrat E. Clinical experience with multispot yellow 577-nm laser. Retinal Phys. 2014;11:29-33.
Mohamed E-E, Mohamed Tawfik K, Hassan Ahmad W. Successful treatment of facial vascular skin diseases with a 577-nm pro-yellow laser. J Cosmet Dermatol. 2019;18(6):1675-1679.
Sarac G, Kapicioglu Y. Efficacy of 577-nm Pro-Yellow laser in port wine stain treatment. Dermatol Ther. 2019;32(6):e13078.
Balaji A, Rashmi K, Devinder M. Scoring systems in acne vulgaris. Indian J Dermatol Venereol Leprol. 2009;75(3):323.